New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
09:14 EDTNPSP, PBYI, CYTK, ARIA, OMER, PCYC, VTR, HCT, PL, Z, BRCM, SHPG, MTZOn The Fly: Pre-market Movers
HIGHER: NPS Pharmaceuticals (NPSP), up 21% after the Times of London reported that Shire (SHPG) secured a $5B credit facility led by Citigroup (C) for a takeover offer for the company... Broadcom (BRCM), up 15% after saying it will explore strategic alternatives for cellular baseband business, backing Q2 revenue expectations... Protective Life (PL) rises 17% after Dai-ichi Life Insurance reported to be in talks to buy the company... American Realty Capital (HCT) up 10% after Ventas (VTR) agreed to acquire the company for $2.6B in stock and cash. Ventas shares down 1.8% in pre-market trade following the deal announcement... Conn's (CONN), up 10% after reporting better than expected Q1 earnings results... ARIAD (ARIA), up 13.5% after FDA lifts partial clinical hold on Iclusig study. LOWER: MasTec (MTZ), down 13% after lowering its Q2 EPS view... Puma Biotechnology (PBYI), down 16% after presentation of PB272 Phase II data... Cytokinetics falls 8.8% after announcing further results from BENEFIT-ALS trial... Zillow (Z), down 4% after shares downgraded at Pacific Crest and at RBC Capital.
News For NPSP;SHPG;BRCM;Z;PL;HCT;VTR;PCYC;OMER;ARIA;CYTK;PBYI;MTZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 15, 2014
10:48 EDTSHPGShire tanks with AbbVie calling board meeting over merger
Subscribe for More Information
10:02 EDTSHPGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:20 EDTSHPGOn The Fly: Pre-market Movers
Subscribe for More Information
09:11 EDTSHPGShire upgraded to Buy from Fair Value at CRT Capital
Subscribe for More Information
07:37 EDTBRCMBroadcom pullback a buying opportunity, says Canaccord
Canaccord said the pullback in Broadcom due to weakness in the semiconductor space is a buying opportunity. The firm believes the company is well positioned for steady long-term growth in its Home and Infrastructure businesses. Canaccord reiterates its Buy rating on Broadcom but lowers its price target to $45 from $46.
07:30 EDTSHPGAbbVie review of Shire deal an 'unwelcome surprise,' says Jefferies
Subscribe for More Information
06:58 EDTSHPGAbbVie volatility elevated into reconsidering Shire merger
Subscribe for More Information
06:55 EDTSHPGShire volatility elevated into AbbVie reconsidering merger recommendation
Subscribe for More Information
06:16 EDTPCYCPharmacyclics initiated with a Buy at Citigroup
Subscribe for More Information
05:34 EDTSHPGShire says AbbVie should proceed with recommended offer
Subscribe for More Information
October 14, 2014
19:50 EDTSHPGShire down nearly 6% following AbbVie reconsidering merger recommendation
Subscribe for More Information
19:48 EDTSHPGAbbVie board reconsidering recommendation to holders to accept Shire merger
Subscribe for More Information
19:46 EDTSHPGAbbVie board reconsidering recommendation to holders to accept Shire merger
Subscribe for More Information
October 13, 2014
08:05 EDTPCYCBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:35 EDTCYTKCytokinetics announces development program update for CK-2127107
Subscribe for More Information
October 10, 2014
12:11 EDTARIAOptions with increasing implied volatility
Subscribe for More Information
10:01 EDTVTROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:00 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
07:46 EDTARIAARIAD announces PRAC of EMA recommends Iclusig for continued EU use
Subscribe for More Information
06:16 EDTVTRVentas upgraded to Buy from Hold at Stifel
Stifel upgraded Ventas to Buy based on valuation. Price target is $70.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use